Randomized, controlled, double-blind trial of taranabant for smoking cessation

• Published in: Psychopharmacologia Vol. 209; no. 3; pp. 245 - 253
• Main Authors: Morrison, Mary F., Ceesay, Paulette, Gantz, Ira, Kaufman, Keith D., Lines, Christopher R.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.04.2010; Springer; Springer Nature B.V
• Subjects: Addictive behaviors; Adolescent; Adult; Adult and adolescent clinical studies; Aged; Amides - adverse effects; Amides - antagonists & inhibitors; Amides - therapeutic use; Behavior, Addictive - drug therapy; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Body Weight - drug effects; Clinical trials; Dose-Response Relationship, Drug; Double-Blind Method; Drug Inverse Agonism; Drugs; Female; Humans; Male; Medical sciences; Middle Aged; Neurosciences; Original Investigation; Pharmacology/Toxicology; Psychiatry; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Pyridines - adverse effects; Pyridines - antagonists & inhibitors; Pyridines - therapeutic use; Receptor, Cannabinoid, CB1 - antagonists & inhibitors; Side effects; Smoking cessation; Smoking Cessation - methods; Tobacco smoking; Tobacco Use Disorder - drug therapy; Tobacco, tobacco smoking; Toxicology; Cannabinoid-1 receptor inverse agonist; Smoking cessation; Randomized clinical trial; Taranabant; Randomization; Poison withdrawal; Inverse agonist; Cannabinoid receptor; Tobacco smoking; Double blind study; Controlled therapeutic trial; Cannabinoid-1 receptor inverse agonist Smoking cessation; Antagonist

Rationale It has been proposed that cannabinoid-1 receptor inverse agonists might be effective for smoking cessation. We evaluated this hypothesis with the cannabinoid-1 receptor inverse agonist taranabant. Methods Adults who smoked ≥10 cigarettes a day for >1 year and had an expired CO level of...